Plandai’s Medical Marij. Research Could Advance From FDA Authorization of Clinical Trials Plandai Biotechnology (OTCQB: PLPL) timed its move into medical marij research perfectly. In Nov. the FDA approved clinical trials of the cannabis-based drug, Epidolex, and its impacts on epilepsy. This approval is a milestone decision by the FDA that puts the drug front and center and may show that the FDA is prepared to accept cannabis as a treatment. The FDA says this epilepsy therapy is 98 percent purified cannabidiol (CBD) made by GW Pharmaceuticals established out of the United Kingdom Plandai, a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, declared at the end of October that it had moved into the pharmaceutical marij business with its new secondary, Cannabis Biosciences, Inc., for the purpose of creating and testing a new Phytofare botanical extract grown from cannabinoids. Plandai (PLPL) hopes to exploit the advantages of phyto-cannabinoids in its extract, Phytofare Phyto-cannabinoid Complex, which is an area the FDA plainly wants to learn more about in its authorization of clinical trials utilizing the cannabis compound.